Generated by AI
MediWound Ltd. is a biopharmaceutical company focused on next-generation enzymatic therapies for non-surgical tissue repair. MediWound develops, manufactures, and commercializes products designed to address severe burns, chronic wounds, and other hard-to-heal tissue injuries. Its portfolio centers on biologic and protein-based treatments that selectively remove damaged tissue while preserving healthy tissue, supporting cleaner wound bed preparation and recovery care. The company serves hospitals, burn centers, and other healthcare providers involved in acute and specialized wound management. MediWound also works across tissue regeneration and related therapeutic areas, positioning itself within the broader wound care and regenerative medicine market. Headquartered in Yavne, Israel, MediWound emphasizes advanced, clinically focused solutions that aim to improve treatment workflows in modern wound care settings.
Website42 Hayarkon Street
Yavne, 8122745
Israel
The latest articles about MDWD.
Summary of May 27's posts. Generated by AI.
Summary of Jul 5's posts. Generated by AI.
Summary of Dec 13's posts. Generated by AI.
Investors talking about MDWD also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.